Navigation Links
Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Date:2/22/2013

ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its flupirtine sublicensee, Meda AB (Meda), has received a green light from the Food and Drug Administration (FDA) to conduct a Phase II proof of concept study for the treatment of fibromyalgia as reported in Meda's 2012 year-end report. Meda has announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted at 25 clinics in the U.S.

In May 2010, the Company entered into an agreement with Sweden-based Meda granting exclusive sublicense to all of its patents and pending patents covering the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. Meda assumed all future development costs for the commercialization of flupirtine for fibromyalgia. Synthetic Biologics received an upfront payment and is entitled to future milestone payments, plus royalties.

"We are pleased to share Meda's update on the status of its clinical development program of flupirtine for fibromyalgia," stated Jeffrey Riley , Chief Executive Officer at Synthetic Biologics. "We believe Meda's experience with flupirtine outside of the U.S. will help bring this potential new class of treatment to the millions of people that suffer from fibromyalgia in the U.S."

About Fibromyalgia and Flupirtine

Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. Fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million patients in the U.S. There are presently three products approved for this indication in
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
4. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
5. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
6. Synthetic Biologics Reports Second Quarter 2012 Financial Results
7. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. Employers Becoming Savvier About Biologics and Specialty Drugs
10. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
11. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... 31, 2015 Today, the National Association ... ) issued a report urging greater accountability by ... taken against websites illegally selling medications online. As ... Identification Program Progress Report for State and Federal ... of websites illegally distribute medications and avoid retribution. ...
(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... Perrigo Company (Nasdaq: PRGO ; TASE) and its ... tentative approval from the U.S. Food and Drug Administration for ... a generic version of UCB,s Xyzal® Oral Solution. Synthon believes ... generic that can entitle it to 180 days of generic ...
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the first quarter ended March 31, 2011 (1). ... Total net revenues in the first quarter of 2011 ...
Cached Medicine Technology:Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3Concord Medical Announces First Quarter 2011 Financial Results 2Concord Medical Announces First Quarter 2011 Financial Results 3Concord Medical Announces First Quarter 2011 Financial Results 4Concord Medical Announces First Quarter 2011 Financial Results 5Concord Medical Announces First Quarter 2011 Financial Results 6Concord Medical Announces First Quarter 2011 Financial Results 7Concord Medical Announces First Quarter 2011 Financial Results 8Concord Medical Announces First Quarter 2011 Financial Results 9Concord Medical Announces First Quarter 2011 Financial Results 10Concord Medical Announces First Quarter 2011 Financial Results 11Concord Medical Announces First Quarter 2011 Financial Results 12Concord Medical Announces First Quarter 2011 Financial Results 13
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... Dallas, TX (PRWEB) , ... August 01, 2015 , ... ... support for the March4thforWellBeing foundation, making hers the very first small business donation to ... and look beautiful for over thirty years. Her legacy includes a complete line of ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... an increased risk of death, by about 12 to 16% ... said a new research published in the latest issue of ... Neonatal and Developmental Medicine, Stanford University, who had done the ... their first month of life than later. Researchers have done ...
... Reddy Saturday administered a "defeat AIDS pledge"// to people ... ,India has 5.13 million people infected with HIV/AIDS. ... in the country with more than 400,000 affected people. ... HIV prevalence rate is an alarmingly 2.25 percent among ...
... easier to diagnose strokes affecting the left-brain than the ... of The Lancet.// ,The authors state that discrepancy ... of right-brain stroke. ,Cerebrovascular events are frequently accompanied ... the brain the lesion occurs. People with events on ...
... it can be marketed as functional food ingredients, or even ... have been able to identify the molecular structure of ... of different flavonols. They also say that they are able ... compounds tailored to specific needs. , ,Several studies in ...
... appears in the current edition of The Lancet said ... high risk from becoming infertile.//, ,Female genital mutilation ... World Health Organization estimates that more than 132 million ... that about 2million procedures are done every year. Few ...
... drug users and HIV infection was done by Chris ... Health. The results of the study showed that an ... countries of Afghanistan to Eastern Europe. “This HIV/AIDS ... ahead of our responses,” says Chris Beyrer. “Drug treatment ...
Cached Medicine News:Health News:"Defeat AIDS Pledge" by Andhra CM 2Health News:Stroke In The Right-Brain Can Remain Undiagnosed 2Health News:Girls Who Undergo Genital Mutilation Can Become Infertile 2Health News:HIV Infection Higher In Drug Trafficking Countries 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: